好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Effects of Lemborexant in the Morning: Results From 3 Randomized Studies
Sleep
S46 - Sleep Science and Therapy Updates (2:06 PM-2:17 PM)
007

Many insomnia treatments are associated with residual morning sleepiness that presents safety risks. LEM has been evaluated for this potential in several studies.

To present results of study endpoints to assess the potential for next-morning residual effects of lemborexant (LEM), a dual orexin receptor antagonist in development for insomnia disorder.

Data presented here are derived from 3 randomized, double-blind, placebo-controlled studies that evaluated LEM 5mg (LEM5) and 10mg (LEM10) in both healthy volunteers and subjects with insomnia. Potential next-morning residual effects were assessed via an on-the-road driving test (Study 1); postural stability (falls risk indicator) and tests of attention and memory shortly after waketime (Study 2 and Study 3); and subject-reported ratings of morning sleepiness/alertness (Study 3).

Study 1: In 48 healthy subjects, there were no statistically significant effects after single or repeated doses of LEM5 or LEM10 on next-morning driving performance. Study 2: In older healthy subjects (n=63; ≥55 years), at 8 hours post-dose, there was no evidence for residual morning effects of LEM5 or LEM10 measured by body sway, or significant effects of LEM5 or LEM10 on tests of attention and memory. Study 3: In older subjects with insomnia (n=1006; ≥55 years), there was a significant increase in morning alertness with LEM5 and LEM10 compared to placebo over the first and last 7 mornings of the 1-month treatment period (p<0.05). Similar to the healthy older subjects in Study 2, there were no significant differences in body sway upon morning awakening, continuity of attention, quality of memory, or speed of memory retrieval for either LEM group versus placebo; only power of attention (reaction time) was slightly but significantly slower than placebo.

Lemborexant at therapeutic dose levels was not associated with clinically important next-morning residual effects as assessed using multimodal, clinically meaningful measures of driving performance, postural stability, and cognition.

Authors/Disclosures
Margaret Moline
PRESENTER
Margaret Moline has received personal compensation for serving as an employee of EISAI, INC.. Margaret Moline has received intellectual property interests from a discovery or technology relating to health care. Margaret Moline has received personal compensation in the range of $0-$499 for serving as a review, loan repayment program with NIH.
Patricia Murphy No disclosure on file
Dinesh Kumar Dinesh Kumar has received personal compensation for serving as an employee of Eisai Inc.
No disclosure on file